Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2004;328:49-50 (3 January), doi:10.1136/bmj.328.7430.49-b
| The first 150 words of the full text of this article appear below. |
EDITORThe National Cancer Research Institute does not set the research strategies of its partners, as Kerrison et al say.1 They also do not grasp its mission, which is to double the number of patients entering cancer clinical trials by 2005 (a target it has already surpassed).
They suggest that the formal research networks in cancer were set up as a result of the outcomes of the Pharmaceutical Industry Competitiveness Taskforce. The institute was created as a result of the high political profile after the publication of the EURO-CARE II data and the subsequent partnership with major governmental and nongovernmental cancer research funders. The taskforce's conclusions post-date establishment of the institute.
The suggestion that "the private sector will have an important role in identifying and implementing research priorities in other disease groups" seems misleading. The private sector, while bringing substantial and welcome funding to cancer research, does not set
Richard Sullivan, head, clinical programmes
Cancer Research UK, London WC2A 3PX richard.sullivan@cancer.org.uk